A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs PRM 151 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Promedior
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2015 Planned End Date changed from 6 Dec 2015 to 1 Mar 2019, as reported by ClinicalTrials.gov.
- 08 Sep 2015 Planned number of patients changed from 60 to 117 according to a Promedior media release.